文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛消化、代谢与肾脏急症

重症监护中的肺孢子菌肺炎:临床谱、预防模式、抗生素治疗延迟的影响及糖皮质激素的作用——法国多中心前瞻性队列研究

Pneumocystis pneumonia in intensive care: clinical spectrum, prophylaxis patterns, antibiotic treatment delay impact, and role of corticosteroids. A French multicentre prospective cohort study.
PubMed 文献 · Intensive Care Med · 2024-06-03
一句话结论重症肺孢子菌肺炎患者ICU入院96小时后启动 curative 抗生素治疗及使用糖皮质激素均与更快的死亡发生相关。

这项法国49个成人ICU的多中心前瞻性观察研究纳入2020年9月至2022年8月的158例肺孢子菌肺炎(PJP)患者,主要入ICU原因为急性呼吸衰竭(150例,94.9%),仅12%在入ICU前接受过PJP抗生素预防。ICU死亡率31.6%、住院死亡率35.4%、6个月死亡率40.5%。采用倾向评分逆概率治疗加权的时间-事件分析显示,入ICU 96小时后启动 curative 抗生素治疗与更快的死亡发生相关(时间比6.75,95%CI 1.48-30.82,P=0.014),使用糖皮质激素亦与更快的死亡发生相关(时间比2.48,95%CI 1.01-6.08,P=0.048)。

要点

  • 158例重症PJP患者中,仅12%在入ICU前接受过PJP抗生素预防。
  • ICU死亡率31.6%、住院死亡率35.4%、6个月死亡率40.5%。
  • 入ICU 96小时后启动 curative 抗生素治疗与更快的死亡发生相关(时间比6.75,95%CI 1.48-30.82,P=0.014)。
  • 使用糖皮质激素与更快的死亡发生相关(时间比2.48,95%CI 1.01-6.08,P=0.048)。
  • 主要入ICU原因为急性呼吸衰竭(150例,94.9%)。

适用人群与场景

  • 法国49个成人ICU收治的需重症监护的重症PJP患者,共158例,纳入时间为2020年9月至2022年8月。
  • 主要入ICU原因为急性呼吸衰竭(n=150,94.9%)。

研究设计与关键结果

  • 研究类型:多中心前瞻性观察研究,纳入法国49个成人ICU的158例重症PJP患者,纳入时间2020年9月至2022年8月。
  • 主要入ICU原因为急性呼吸衰竭(n=150,94.9%);12%的患者在入ICU前接受过PJP抗生素预防。
  • ICU死亡率31.6%,住院死亡率35.4%,6个月死亡率40.5%。
  • 采用倾向评分逆概率治疗加权的时间-事件分析:入ICU 96小时后启动 curative 抗生素治疗与更快的死亡发生相关(时间比6.75;95%CI 1.48-30.82;P=0.014)。
  • 使用糖皮质激素与更快的死亡发生相关(时间比2.48;95%CI 1.01-6.08;P=0.048)。

证据类型、等级与局限

  • 证据类型:多中心前瞻性观察性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,延误 curative 抗生素治疗与辅助糖皮质激素均与重症PJP患者加速死亡相关,提示应关注早期启动 curative 抗生素治疗及谨慎评估糖皮质激素的使用。
  • 研究显示仅12%的重症PJP患者在入ICU前接受过抗生素预防,提示预防覆盖可能不足。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Severe Pneumocystis jirovecii pneumonia (PJP) requiring intensive care has been the subject of few prospective studies. It is unclear whether delayed curative antibiotic therapy may impact survival in these severe forms of PJP. The impact of corticosteroid therapy combined with antibiotics is also unclear.

METHODS: This multicentre, prospective observational study involving 49 adult intensive care units (ICUs) in France was designed to evaluate the severity, the clinical spectrum, and outcomes of patients with severe PJP, and to assess the association between delayed curative antibiotic treatment and adjunctive corticosteroid therapy with mortality.

RESULTS: We included 158 patients with PJP from September 2020 to August 2022. Their main reason for admission was acute respiratory failure (n = 150, 94.9%). 12% of them received antibiotic prophylaxis for PJP before ICU admission. The ICU, hospital, and 6-month mortality were 31.6%, 35.4%, and 40.5%, respectively. Using time-to-event analysis with a propensity score-based inverse probability of treatment weighting, the initiation of curative antibiotic treatment after 96 h of ICU admission was associated with faster occurrence of death [time ratio: 6.75; 95% confidence interval (95% CI): 1.48-30.82; P = 0.014]. The use of corticosteroids for PJP was associated with faster occurrence of death (time ratio: 2.48; 95% CI 1.01-6.08; P = 0.048).

CONCLUSION: This study showed that few patients with PJP admitted to intensive care received prophylactic antibiotic therapy, that delay in curative antibiotic treatment was common and that both delay in curative antibiotic treatment and adjunctive corticosteroids for PJP were associated with accelerated mortality.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Kamel T, Janssen-Langenstein R, Quelven Q, et al. Pneumocystis pneumonia in intensive care: clinical spectrum, prophylaxis patterns, antibiotic treatment delay impact, and role of corticosteroids. A French multicentre prospective cohort study. Intensive Care Med. 2024. PMID: 38829531. doi:10.1007/s00134-024-07489-2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。